Innovate UK

Biovit is a company that specializes in the development of fortified foods. It uses 100% organic plant extracts, naturally rich in vitamins and minerals, to enhance the nutritional value of its products. The company aims to address health and environmental issues such as obesity and malnutrition, while also reducing food waste. Biovit has clinically tested and developed organic micronutrient blends for use in various food and beverage products, as well as supplements, providing consumers with organically sourced, nutrient-dense options.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

The Good Pulse Co. specializes in producing functional proteins and ingredients derived from pulses, such as peas and soy, for use in plant-based foods and supplements. The company is dedicated to creating alternatives to traditional meat and cheese products through precision fermentation, aiming to enhance functionality and nutrition while promoting sustainability. By maximizing the value of all components extracted from pulse seeds, The Good Pulse Co. offers consumers a more efficient and ethical way to enjoy nutritious food without compromising on taste or experience.

Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.

Camallergy Limited, based in Cambridge, United Kingdom, is a biopharmaceutical company established in 2015 that focuses on developing and manufacturing oral immunotherapy drugs and other pharmaceutical products specifically for food allergies. The company's primary offering is a novel oral immunotherapy designed to treat peanut allergies, which aims to provide patients with "bite-proof" protection within 14 weeks of therapy. This patient-centric treatment addresses the urgent needs of millions suffering from food allergies and is rooted in clinical research conducted at Cambridge University Hospitals NHS Foundation Trust. Camallergy's unique intellectual property and treatment regimen exemplify its commitment to improving the quality of life for individuals affected by these allergies.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, that specializes in contract research and manufacturing services focused on drug discovery. Established in 2001, the company provides a comprehensive range of services, including medicinal and computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex is known for its expertise in developing advanced medicines through innovative technologies, including biochemical binding techniques, particularly for oncology drugs and treatments for inflammatory diseases. The company has a significant emphasis on hit identification and candidate drug synthesis, utilizing both virtual and fragment-based approaches to address complex drug discovery challenges. In 2007, Domainex merged with NCE Discovery, enhancing its capabilities in both biological and chemical research.

CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.

Nandi Proteins Limited is a technology-driven company based in Edinburgh, United Kingdom, focused on enhancing the functional properties of proteins in food manufacturing and nutrition. Established in 2000 and spun out of Heriot Watt University in 2001, the company specializes in patented processes that improve common proteins such as whey, egg, and soy. Nandi Proteins aims to be a leader in denatured protein technology, facilitating growth through direct trading of value-added proteins and strategic licensing agreements with industry partners. Its innovative approach employs a combination of heat, time, and temperature control to modify proteins, enabling food and beverage manufacturers to achieve desirable characteristics and health benefits while efficiently extracting valuable components like enzymes.